International Assets Investment Management LLC Buys 5,705 Shares of Insulet Corporation $PODD

International Assets Investment Management LLC lifted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 7,815.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,778 shares of the medical instruments supplier’s stock after buying an additional 5,705 shares during the quarter. International Assets Investment Management LLC’s holdings in Insulet were worth $756,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Elevation Wealth Partners LLC increased its position in Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 104 shares during the period. Activest Wealth Management increased its holdings in shares of Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 149 shares during the period. WPG Advisers LLC boosted its stake in Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 171 shares during the period. Covestor Ltd boosted its stake in shares of Insulet by 103.9% during the third quarter. Covestor Ltd now owns 310 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 158 shares during the period. Finally, Continuum Advisory LLC acquired a new stake in Insulet during the 2nd quarter worth approximately $46,000.

Insulet Price Performance

Insulet stock opened at $148.06 on Wednesday. The stock has a market capitalization of $10.27 billion, a P/E ratio of 24.11, a P/E/G ratio of 1.14 and a beta of 1.06. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The firm’s 50-day moving average is $142.05 and its two-hundred day moving average is $175.32.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business’s revenue was up 19.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.24 earnings per share. Equities analysts predict that Insulet Corporation will post 6.75 earnings per share for the current year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Truist raised its price target to $160 from $153 while maintaining a “hold” rating, implying potential upside from the cited share price. Truist price target
• Positive Sentiment: A separate report said Insulet’s growth characteristics could help it outperform the market, though it did not provide specific new financial guidance. Zacks growth-stock analysis
• Neutral Sentiment: Insulet launched a World Diabetes Day campaign encouraging people with diabetes to prioritize well-being. The initiative may support awareness but does not indicate a direct near-term financial impact. World Diabetes Day campaign
• Neutral Sentiment: A short-interest update reported zero shares sold short and a 0.0-day days-to-cover ratio, despite describing short interest as having increased. The figures therefore do not point to meaningful short-squeeze activity.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PODD shares. Raymond James Financial reaffirmed an “outperform” rating and set a $180.00 price target on shares of Insulet in a report on Thursday, August 6th. UBS Group lifted their target price on shares of Insulet from $150.00 to $171.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group lowered their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $200.00 target price on shares of Insulet in a research note on Wednesday, November 4th. Twelve analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $185.67.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.